CMPX Compass Therapeutics Inc

Price (delayed)

$2.135

Market cap

$384.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.4

Enterprise value

$338.54M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 6

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in ...

Highlights
Compass Therapeutics's quick ratio has soared by 150% YoY and by 27% from the previous quarter
The EPS rose by 4.8% since the previous quarter and by 2.4% year-on-year
The equity has soared by 69% YoY but it has contracted by 5% from the previous quarter
Compass Therapeutics's gross profit has plunged by 100% YoY
Compass Therapeutics's revenue has plunged by 100% YoY

Key stats

What are the main financial stats of CMPX

CMPX stock price

How has the Compass Therapeutics stock price performed over time
Intraday
1.67%
1 week
-11.41%
1 month
10.05%
1 year
-1.61%
YTD
-60.24%
QTD
-59.64%

Financial performance

How have Compass Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$75.17M
Net income
-$68.17M
Gross margin
N/A
Net margin
N/A
Compass Therapeutics's gross profit has plunged by 100% YoY
Compass Therapeutics's revenue has plunged by 100% YoY
The net income has declined by 23% year-on-year and by 2.5% since the previous quarter
The operating income has decreased by 22% YoY and by 3.2% from the previous quarter

Price vs fundamentals

How does CMPX's price correlate with its fundamentals

Growth

What is Compass Therapeutics's growth rate over time

Valuation

What is Compass Therapeutics stock price valuation
P/E
N/A
P/B
2.06
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 4.8% since the previous quarter and by 2.4% year-on-year
The equity has soared by 69% YoY but it has contracted by 5% from the previous quarter
CMPX's price to book (P/B) is 49% lower than its last 4 quarters average of 4.0 and 15% lower than its 5-year quarterly average of 2.4
Compass Therapeutics's revenue has plunged by 100% YoY

Efficiency

How efficient is Compass Therapeutics business performance
The ROIC has grown by 15% YoY and by 9% from the previous quarter
The return on equity is up by 9% since the previous quarter and by 7% year-on-year
Compass Therapeutics's return on assets has increased by 8% YoY and by 7% QoQ

Dividends

What is CMPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CMPX.

Financial health

How did Compass Therapeutics financials performed over time
Compass Therapeutics's quick ratio has soared by 150% YoY and by 27% from the previous quarter
CMPX's current ratio has soared by 129% YoY and by 27% from the previous quarter
CMPX's debt is 95% smaller than its equity
The equity has soared by 69% YoY but it has contracted by 5% from the previous quarter
CMPX's debt has surged by 53% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.